Contact

General Counsel

Mrs. Matar is an experienced and dedicated executive lawyer and legal consultant specialized in working in global companies. Yael gained special expertise in day-to-day legal counseling to all units of a company, commercial transactions, strategic alliances, corporate, labor, intellectual property, compliance, and regulation.  Mrs. Matar is an international lawyer licensed in Israel (2004), holds LL.B (with Distinct Honors) and LL.M (with excellence) from Tel Aviv University.

We are looking for a global quality assurance manager for the company, operating in the field of pharma – medical cannabis. Reporting to the company COO.

Job Description:

Overall responsibility for all quality assurance aspects and activities in manufacturing and research and development, in Israel and abroad.

Leading the company Global QA team.

Responsibility for developing and implementing quality systems on the various sites, managing ongoing control, building training and certificate systems.

Role requirements and previous experience:

B.A. in Life Sciences/Engineering/ Industry and Management/Quality.

Proven experience of at least 5 years in developing and managing global quality assurance systems at GMP certified sites from the pharma industry.

Experience in GMP reviews.

English – high-level.

Job Description:

Operator/technician at a cannabis manufacturing plant

Partner in the process of establishing a pharmaceutical production system

Executing productions and packaging

Working in a pharmaceutical manufacturing environment, under GMP conditions, according to quality procedures and working instructions

Operation of manufacturing and packaging machines, integrated automation, and computerized control.

Perform all tasks in manufacturing processes from raw materials to final product shipping Logistics – absorption of raw materials, issue to the factory, absorption, and management of inventory in the process and finished produce.

Operating workstations according to work procedures and instructions

Performing and documenting manufacturing operations according to GMP requirements

Closing the workstations and preparing the rooms and equipment for further production.

Role requirements and previous experience:

Working Experience within pharmaceutical production systems

Performing the role of the operator in Pharma manufacturing production floor

Ability to follow procedures and follow working instructions in a GMP environment.

writing and documentation

Managing documentation – Documents Knowledge as diverse as possible in manufacturing equipment, support systems (water, gases, HVAC)

English at Entry-level

Ability to perform a wide variety of roles from different professions in the production system

Job Description: 

Reports to VP R&D

Classification: Full-time

M.H MediCane is looking for a senior clinical program manager to manage all of MediCane’s clinical program aspects

The requirements listed below are representative of the knowledge, skill, and abilities required:

• Achieve study objectives by working with team members to set project priorities and milestones and resolve project conflicts
• Organize and lead the clinical project teams of multiple parallel clinical trials.
• Manage, coordinate, and supervise all aspects of work with CROs and other clinical program vendors (Israel and worldwide).
• Lead the development of study-related documents, including study synopsis, study protocols, informed consent documents, study manuals, and plans, trial master files, case report form design, etc.
• Monitor trial progress (timelines, budget) and initiate appropriate actions to achieve objectives.
• Maintain professional expertise through familiarity with the therapeutic area and clinical research literature
• Manage clinical projects from concept through clinical study report completion
• Oversee clinical research study conduct
• Lead scheduled cross-functional clinical program team meetings
• Participates in CRO and other vendor selection, negotiation, and management, including monitoring of associated budgets and contracts
• Participate in meetings with investigative sites, key opinion leaders, and consultants as needed
• Plays a part in the analysis, summary, and reporting of clinical data through the course of the study
• Aid in the training and development of all clinical staff members
• Responds promptly to study questions and issues raised by investigative sites, vendors, monitors, consultants, and sponsors
• Ensures GCP and regulatory compliance is maintained
• Create and implement study-specific clinical monitoring tools and documents
• Assesses the operational feasibility of studies and recommends execution and risk mitigation plans
• Coordinate site management activities

• Build and Assure compliance with SOPs and all regulatory guidelines.

Education/Experience:

• Bachelor’s and/or master’s degree in a scientific discipline (Master’s degree in Regulatory Affairs, Health Policy or similar preferred), RN, BSN degree or equivalent
• CRA certification is strongly preferred
• A minimum of 5+ years of clinical trial operations experience, with increasing levels of responsibility, in the Pharmaceutical, Biotechnology, Medical Device and/or CRO industry is required.
• Five or more years of clinical program management experience at a sponsor or CRO company
• Prior management experience is required
• Prior monitoring and clinical project management experience are required.
• Therapeutic experience in Neurology and/or inflammatory diseases (preferred)
• Experience in early phase trials (Phase I-II), Know-how in managing Phase I, II, & III clinical studies

Knowledge, Skills, and Abilities:

• Team player, willing to work in the vibrant and energetic environment of a startup company
• Read, write and speak fluent English; excellent verbal and written communication skills
• Experience in writing clinical study protocols, informed consent forms, and other clinical documents
• Solid understanding of FDA and other regulatory requirements that may impact global clinical studies
• Thorough knowledge of GCP, ICH guidelines, and regulatory requirements for clinical trial management
• Willing and capable to manage multiple projects, negotiate budgets, timelines, and responsibilities
• Working knowledge of MS Project for development and update of clinical study timelines
• Willingness to travel in Israel and abroad

CEO MediCane Australia

Mr. Katz is a former Asia Pacific CEO of a leading international FMCG retailer, with vast global management experience in diverse service and retail business units. He is a qualified lawyer and has held senior positions and advisory roles in the fields of management consulting, general management, retail leasing, franchising and corporate strategy for local and global organizations. He holds a bachelor’s degree in law and a B. Comm. (Honours) from the University of Cape Town.

CEO MediCane Portugal

Mrs. Broder-Koshet is an experienced strategic and marketing planning specialist with expertise in devising and implementing business strategies in global markets. As former Marketing Manager at AT&T Israel, she has a strong background in handling large budgets and establishing corporate partnerships in a variety of countries. She holds a B.Sc. in International Business Administration from the American College of Switzerland, and an M.Sc. in Business Management from Boston University.

CSB Germany

Mr. Quodt is a health care adviser with over 35 years of comprehensive experience working in the research-driven pharmaceutical industry in senior executive positions across Europe and the U.S. During his career he also served as chairman/co-chairman of national pharmaceutical associations. Currently he is advising investment groups and start-up ventures in the health care, food and consumer goods industry. He holds a degree in Business Administration and Market Psychology from the University of Munich, Germany.

Global Supply Chain Lead

Mr. Codner is MediCane’s Distribution Director since April 2019 with an extensive background in pharmaceuticals, finance, and logistics. Richard is the former Executive Director of Global Market Access at Merck, Sharp, and Dohme (MSD). He served as MSD’s European Director of Distribution 12 years. Earlier he was a Finance Director at 3M. He is a CPA in the state of California and in Israel with experience in tax and audit at KMPG in his native Los Angeles. Richard earned a magna cum laude BA in Psychology at Brown University and an MBA at University of Southern California.

General Counsel

Ms. Shaul-Shalem is a legal expert and a public notary with a comprehensive experience in providing legal consulting services to corporate clients in the medical, pharmaceutical and biotechnological industries. She specializes in commercial law, business and human resource matters, commercial procurement activities, compliance, negotiations with regulatory agencies, and global third-party partnerships. She holds an L.L.B. in Law Studies and a B.A. in Business Administration from the Herzliya Interdisciplinary Center, and an L.L.M. in Law Studies from Bar Ilan University.

Professor of Pathology and Cell Biology, Columbia University Erving Medical Center

Dr. Israely carried out her PhD research at the University of California, Los Angeles, in the laboratory of Drs. Xin Liu and Alcino Silva, where she demonstrated that loss of a neural specific cell adhesion protein linked to disease, delta-catenin, results in cognitive dysfunction.  Dr. Israely joined Dr. Susumu Tonegawa’s lab at MIT for her postdoctoral training, where she used two-photon imaging and glutamate uncaging to uncover the learning rules associated with long lasting structural and functional changes at individual synapses. In 2009, she started her own group at the Champalimaud Foundation, and in 2016, the lab relocated to Columbia University, in the Taub Institute for Research on Alzheimer’s Disease and the Aging Brain, within the departments of Pathology and Cell Biology and Neuroscience. She uncovered dynamic interactions between spines during synaptic plasticity, such as cooperation and competition, that are critical for the long term storage of information in the brain. Dr. Israely’s laboratory uses genetic, electrophysiological, optical and molecular approaches to study how activity dependent structural changes shape neural circuits, and how when impaired, these contribute to neurodevelopmental disorders, including autism, and neurodegeneration.

Director of Clinical Neurosciences at St. Vincent’s Hospital, Melbourne: Chair of Medicine at the University of Melbourne

Prof. Cook is the Director of Clinical Neurosciences at St. Vincent’s Hospital, as well as the Director of the Graeme Clark Institute and the Sir John Eccles Chair of Medicine at the University of Melbourne. After completing specialist training in Melbourne, he undertook an M.D. thesis while working as Brain Research Fellow at Queen Square, London. He returned to St. Vincent’s Hospital to continue his interest in neuroimaging and management of complex epilepsy.

Prof. Cook specializes in the treatment of epilepsy and is recognized internationally for his expertise in epilepsy management, particularly imaging and surgical planning. He has worked closely with engineers for most of his career, developing novel therapies for epilepsy. His interests have included experimental models of epilepsy and seizure prediction, and he has led the commercialization of an implantable seizure detection device about to start clinical trials.

Professor of Psychological and Brain Sciences, Indiana University Bloomington

Prof. Bradshaw completed her B.Sc. in Nutrition and PhD in Neuroscience at Florida State University with focus on peripheral inflammation and visceral pain across the hormonal cycle. She completed her postdoctoral studies at Brown University investigating the role of the endocannabinoid system in pain and inflammation and is currently a Professor of Psychological and Brain Sciences at Indiana University. Her research combines the fields of neurophysiology, behavior, and lipid biochemistry to understand how lipid signaling drives changes in cellular communication.

Prof. Bradshaw’s work demonstrated that lipoamines and related lipids, prostaglandins, are differentially regulated by each of the enzymes and receptors associated with the endogenous cannabinoid system and that the active compounds in Cannabis, THC and CBD, likewise regulate these classes of lipids.  Prof. Bradshaw serves on the International Cannabinoid Research Society board since 2016 and was recently elected as the ICRS liaison to and Associate Editor for the Cannabis and Cannabinoid Research journal.

Professor of Neuroscience and Neurology: Director and CEO of Zuckerman Mind Brain Behavior Institute, Columbia University

Prof. Costa received his D.V.M. from the University of Lisbon. He completed his Ph.D. studies with Dr. Alcino Silva at UCLA followed by postdoctoral work with Dr. Miguel Nicolelis at Duke University. Prof. Costa became a Section Chief at the National Institutes of Health in 2006, and in 2009 became an Investigator of the Champalimaud Neuroscience Program. From 2011 to 2013 he served as Deputy Director, and from 2014 to 2017 – as Director of Champalimaud Research.

Prof. Costa uses genetic, electrophysiological, optical, and behavioral approaches to investigate the mechanisms underlying the generation and learning of novel actions. He also studies disorders that lead to problems with action initiation, compulsive behaviors, and habits. He has received the Young Investigator Award from the Society for Neuroscience and the Jean-Louis Jeantet Foundation, the Ariëns Kappers Medal from the Royal Netherlands Academy of Arts and Sciences and was knighted Commander of the Order of Sant’Iago da Espada. He is an elected member of EMBO and the National Academy of Medicine.

Job Description:

Full-time position-regular working hours

Location in Kfar Saba

Directly reporting to the company’s Finance Director

Role requirements and previous experience:

Level 3 in accounting

3-5 years of experience

Experience in authorities’ submissions VAT and Tax

Proven experience and capabilities in performing “month-end closing” to the level of “balance closing”.

Experience working with ERP systems Priority \ NetSuite \ SAP

Ability to write and communicate in English, at a high level

Chair of the Scientific Advisory Board

Dr. Weiner studied Organic Chemistry at the Hebrew University of Jerusalem, completed his Ph.D. in Chemistry in 1972, and had his postdoctoral fellowship training at Schering-Plough Corporation in the United States. He started working in Teva Pharmaceuticals in 1975, and since then served in various prominent R&D positions, including VP R&D and Senior Global VP R&D. He was granted the Rothschild Prize for Industrial Innovation twice: in 1989 for the development of Alpha D3 for kidney and bone disorders, and in 1999 for the development of Copaxone(R) for multiple sclerosis. During his 37-year career at Teva, Dr. Weiner was responsible for the introduction and FDA approvals of numerous products in the U.S. and other countries, including “simple” generics, value added generics and bio-similar biologic product development. Under his leadership multiple innovative products were developed and later on launched worldwide, including Copaxone(R) for multiple sclerosis (with billions of dollars peak sales a year), Azilect for Parkinson’s disease, and many others. Dr. Weiner retired from Teva in 2012, and currently holds scientific advisory board positions in various pharmaceutical companies.